Literature DB >> 30879219

ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population.

Efthimios Dardiotis1, Emmanouil Karampinis2, Vasileios Siokas2, Athina-Maria Aloizou2, Dimitrios Rikos2, Styliani Ralli2, Dimitra Papadimitriou3, Dimitrios P Bogdanos4,5, Georgios M Hadjigeorgiou6.   

Abstract

BACKGROUND: Α number of genetic variants have been associated with amyotrophic lateral sclerosis (ALS). A recent study supports that rs591486 across the ERCC6L2 gene and exposure to pesticides seem to have a joint effect on the development of Parkinson's disease, a disease which shares a few common characteristics with ALS.
OBJECTIVE: To detect a possible contribution of rs591486 ERCC6L2 to ALS.
METHODS: A total of 155 patients with ALS and 155 healthy controls were included in the study and genotyped for rs591486. Using logistic regression analyses (crude and adjusted for age and sex), rs591486 was tested for association with ALS risk. Subgroup analysis based on ALS site of onset was also performed. Cox regression analysis was applied in order for the effect of ERCC6L2 rs591486 on ALS age of onset to be tested.
RESULTS: Adjusted analysis showed that ERCC6L2 rs591486 was associated with an increased risk of ALS development, in dominant [odds ratio, OR (95% confidence interval, CI) 2.15 (1.04-4.46), p = 0.037] and over-dominant [OR (95%CI) = 1.91 (1.01-3.60), p = 0.043], modes. Subgroup analysis based on ALS site of onset revealed an association between ERCC6L2 rs591486 and ALS with limb onset. Results for Cox regression analysis indicated that G/A carriers had a lower age of ALS limb onset when compared to G/G carriers.
CONCLUSIONS: The current study provides preliminary indication for an implication of ERCC6L2 rs591486 in ALS development, as a possible genetic risk factor. These results possibly suggest that oxidative stress may be the main contributor in the pathophysiology of ALS.

Entities:  

Keywords:  ALS; ERCC6L2; Oxidative stress; Pesticides; Polymorphism

Mesh:

Substances:

Year:  2019        PMID: 30879219     DOI: 10.1007/s10072-019-03825-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  5 in total

1.  Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Authors:  Polyxeni Stamati; Vasileios Siokas; Athina-Maria Aloizou; Emmanouil Karampinis; Stylianos Arseniou; Valerii N Rakitskii; Aristidis Tsatsakis; Demetrios A Spandidos; Illana Gozes; Panayiotis D Mitsias; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

2.  Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-03       Impact factor: 3.307

3.  Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Ioannis Liampas; Zisis Tsouris; Alexios-Fotios A Mentis; Grigorios Nasios; Dimitra Papadimitriou; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Mol Biol Rep       Date:  2021-04-07       Impact factor: 2.316

4.  Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Ioannis Liampas; Christos Bakirtzis; Grigorios Nasios; Konstantinos Paterakis; Markos Sgantzos; Dimitrios P Bogdanos; Demetrios A Spandidos; Aristidis Tsatsakis; Panayiotis D Mitsias; Efthimios Dardiotis
Journal:  Mol Med Rep       Date:  2022-03-02       Impact factor: 2.952

5.  MOBP rs616147 Polymorphism and Risk of Amyotrophic Lateral Sclerosis in a Greek Population: A Case-Control Study.

Authors:  Ioannis Liampas; Vasileios Siokas; Athina-Maria Aloizou; Christos Bakirtzis; Zisis Tsouris; Anastasia Nousia; Grigorios Nasios; Dimitra Papadimitriou; Panagiotis Liakos; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Medicina (Kaunas)       Date:  2021-12-07       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.